Reta 40mg

Description

Retatrutide 40mg

Retatrutide 40mg research peptide for laboratory and scientific research. This high-strength lyophilized peptide is supplied for qualified research applications and is intended strictly for laboratory, analytical and scientific use.

Retatrutide 40mg Australia

Retatrutide, also known as LY3437943, is an investigational peptide being studied for its activity across three metabolic hormone receptors: GIP, GLP-1 and glucagon (GCG).

Because of this multi-receptor activity, retatrutide has become an important subject of metabolic, energy-balance and body-composition research.

MediTech Plus Australia supplies Retatrutide 40mg as a research-use peptide, with batch-focused quality documentation, third-party testing and Australian-based dispatch.

Explore our wider Research Peptides collection to discover additional compounds used in laboratory and scientific research.

What Is Retatrutide?

Retatrutide is an investigational triple hormone receptor agonist that activates the GIP, GLP-1 and glucagon receptors.

Unlike single-pathway peptide compounds, retatrutide is being studied because of its simultaneous activity across three receptor systems involved in metabolic regulation.

A Phase 2 clinical trial published in the New England Journal of Medicine investigated retatrutide in adults with obesity. The study reported dose-dependent changes in body weight over 48 weeks and identified retatrutide as a GIP, GLP-1 and glucagon receptor agonist.

External research: Read the peer-reviewed retatrutide research on PubMed.

Retatrutide 40mg Product Specifications

Always review the batch-specific documentation supplied with the product before laboratory use.

Retatrutide Research Areas

Retatrutide is currently of interest across several areas of scientific investigation, including:

• Metabolic research
• Energy-balance research
• Appetite regulation research
• Body-composition research
• GIP receptor research
• GLP-1 receptor research
• Glucagon receptor research
• Multi-receptor peptide research
• Peptide pharmacology

These represent areas of scientific investigation and should not be interpreted as approved medical applications.

Why Researchers Choose Retatrutide 40mg

MediTech Plus Australia’s current product information highlights several research-supply features:

• 40mg retatrutide per vial
• High-purity lyophilized formulation
• Third-party tested batches
• Batch verification availability
• Australian-held stock
• Cold-stored inventory
• Fast Australia-wide dispatch
• Protective research-product packaging

For additional information about product testing documentation, visit the Certificate of Analysis (COA) page.

Retatrutide and the Triple-Receptor Approach

One of the defining characteristics of retatrutide is its activity across three hormone receptors.

GIP

GIP stands for glucose-dependent insulinotropic polypeptide. GIP-related signalling is an important area of metabolic research.

GLP-1

GLP-1, or glucagon-like peptide-1, is involved in several physiological processes related to glucose regulation and appetite.

Glucagon

Glucagon plays an important role in energy metabolism and glucose homeostasis.

Retatrutide’s combined activity across these three pathways is why it is commonly described in scientific literature as a triple agonist.

Retatrutide Clinical Research

Retatrutide remains an investigational compound and continues to be studied in clinical research.

In a Phase 2 randomized, placebo-controlled trial, researchers evaluated several retatrutide dose groups over 48 weeks. The study found substantial, dose-dependent reductions in body weight in participants receiving retatrutide compared with placebo.

The same research also assessed safety outcomes and metabolic measures, providing important data for the continued investigation of retatrutide.

Research source: New England Journal of Medicine – Retatrutide Phase 2 Trial.

Retatrutide vs Other Metabolic Research Peptides

Retatrutide differs from many other metabolic research peptides because it is designed to interact with three receptor pathways.

For researchers comparing metabolic research compounds, it can be useful to examine retatrutide alongside other compounds such as Cagrilintide and Tirzepatide.

You can explore the MediTech Plus Australia catalogue for additional Metabolic Research products.

Retatrutide 40mg for Laboratory Research

The 40mg format provides researchers with a higher-quantity research material for appropriate laboratory applications.

The product is supplied as a lyophilized powder and should be handled according to the applicable laboratory protocol, product documentation and institutional safety requirements.

No human-use dosing, administration or treatment instructions are provided because this product is supplied strictly for research purposes.

Quality Testing and Batch Verification

Research material quality and traceability are important when selecting laboratory compounds.

MediTech Plus Australia states that its Retatrutide 40mg product is supplied from third-party tested batches and that batch verification is available. The website also provides a dedicated Certificate of Analysis page for research-product documentation.

Researchers should review the relevant batch documentation and verify that the supplied material meets the requirements of their intended research protocol.

Australian Retatrutide Research Supply

For researchers searching for Retatrutide 40mg Australia, MediTech Plus Australia provides Australian-held research stock with Australia-wide dispatch.

The current product listing identifies Reta 40mg within the site’s Metabolic Research and Research Peptides categories.

Explore the broader research catalogue to compare available metabolic research compounds and laboratory supplies.

Frequently Asked Questions

What is Retatrutide 40mg?

Retatrutide 40mg is a research peptide containing 40mg of retatrutide in a lyophilized powder format. It is supplied strictly for laboratory and scientific research.

What is retatrutide also called?

Retatrutide is also known by the development code LY3437943.

What receptors does retatrutide target?

Retatrutide is an investigational triple agonist of the GIP, GLP-1 and glucagon receptors.

What is retatrutide researched for?

Research has investigated retatrutide in areas including metabolic regulation, energy balance, appetite, body composition and weight-related outcomes.

Is Retatrutide 40mg for human use?

No. This product is supplied strictly for laboratory and scientific research and is not intended for human or veterinary consumption.

Does Retatrutide 40mg come with batch verification?

The current MediTech Plus Australia product listing states that third-party tested batches and batch verification are available.

Where can I read scientific research about retatrutide?

Peer-reviewed research is available through PubMed, while detailed clinical-trial publications can be accessed through the New England Journal of Medicine and registered trial databases.

Important Research-Use Disclaimer

Retatrutide 40mg is supplied strictly for laboratory, analytical and scientific research purposes.

This product is not intended for human or veterinary consumption and is not supplied for the diagnosis, treatment, cure or prevention of any disease.

Researchers are responsible for ensuring that purchasing, storage, handling and use comply with all applicable laws, regulations, laboratory procedures and institutional requirements.

Explore More Research Peptides

Explore the MediTech Plus Australia range of Research Peptides and Metabolic Research products for additional laboratory research compounds.

For related research areas, you can also explore Cagrilintide, Tirzepatide and other metabolic research products available through the MediTech Plus Australia catalogue.

📅 Last updated: November 6, 2026